Journal of Neural Transmission

Article	Citations
Facets of movement disorders– a tribute to Heinz Reichmann	144
Alterations in metabolites in the anterior cingulate cortex and thalamus and their associations with pain and empathy in patients with chronic mild pain: a preliminary study	97
Celebrating the career of professor Zdravko Lacković: a life in neuroscience, pharmacology, and discovery	95
Neuromodulation of excitation-inhibition balance in dementia with lewy bodies: a translational framework	91
EEG power spectral and microstate analyses in the 22q11.2 deletion syndrome: from genetic risk to schizophrenia	79
Dopamine agonists in the treatment of Parkinson's disease: the show must go on	73
Eye movement study in essential tremor patients and its clinical correlates	73
Do demographic and clinical features and comorbidities affect the risk of spread to an additional body site in functional motor disorders?	71
Structural MRI in frontotemporal dementia and Alzheimer’s disease: stage-dependent atrophy patterns	61
Stress enhances heartbeat-evoked potentials, independent of continuous or intermittent theta burst stimulation of the interoceptive brain network targeting the right supramarginal gyrus: a preliminary	61
Far from being the end of the road: taking a closer look at neuropalliative care in Parkinson’s disease	57
Contrasting features between Tourette syndrome and secondary tic disorders	55
Movement disorders associated with diarrhoea	54
Pathogenesis of Parkinson’s disease: from hints from monogenic familial PD to biomarkers	52
A kynurenine pathway enzyme aminocarboxymuconate-semialdehyde decarboxylase may be involved in treatment-resistant depression, and baseline inflammation status of patients predicts treatment response:	49
Movement disorders with autoimmune neuromuscular origin: an overview of Isaacs’ syndrome, stiff person syndrome, immune-mediated rippling muscle disease	48
Sitagliptin attenuates L-dopa-induced dyskinesia by regulating mitochondrial proteins and neuronal activity in a 6-OHDA-induced mouse model of Parkinson’s disease	45
A wearable device-enabled therapeutic approach to improve joint attention in autism spectrum disorder: a prospective pilot study	39
Current perspectives on brain circuits involved in food addiction-like behaviors	36
Cholinergic neurotransmission in the brain of streptozotocin-induced rat model of sporadic Alzheimer’s disease: long-term follow up	35
Unusual delayed and prolonged arm weakness and atrophy following botulinum toxin injection for musician’s cramp: case report	33
Association between autonomic dysfunction with motor and non-motor symptoms in patients with Parkinson's disease	31
Botulinum toxin effects on biochemical biomarkers related to inflammation-associated head and neck chronic conditions: a systematic review of clinical research	31
Non motor Parkinson: subtypes, biomarkers, stepped care and a journal!	31
The spectrum of behavioral disorders in amyotrophic lateral sclerosis: current view	28

Understanding cognitive features of cervical dystonia: application of the cerebellar cognitive affective syndrome scale (CCAS-S)	27
Unravelling head tremor mechanisms: insights from speech analysis in essential tremor and cervical dystonia	27
The potential role of kynurenine pathway and inflammation in pediatric obsessive-compulsive disorder with and without major depressive disorder comorbidity	26
COMT inhibition with entacapone for patients with Parkinson’s disease and motor complications: the novelty of continuous infusion	25
Bradykinesia and rigidity modulated by functional connectivity between the primary motor cortex and globus pallidus in Parkinson’s disease	25
The social cost of facial bradykinesia: a scoping review of interpersonal outcomes related to Parkinsonian hypomimia	25
The pathobiology of depression in Huntington’s disease: an unresolved puzzle	24
The role of immune and inflammatory-related indicators in cognitive dysfunction and disease severity in patients with parkinson’s disease	24
Botulinum toxin and conservative treatment strategies in people with cervical dystonia: an online survey	23
Camillo Golgi’s contributions to the anatomic basis of sensitivity in tendons	23
Botulinum toxin for chronic migraine	23
Old problems, new solutions: harnessing technology and innovation in Parkinson’s disease—evidence and experiences from Thailand	23
Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016	23
Comparison of inflammatory biomarker levels in neurodegenerative proteinopathies: a case-control study	23
Cerebral glucose metabolism: the potential missing link in autism research—a literature review and meta-analytic synthesis	22
The German Parkinson expert meetings	21
Impact of APOE and MAPT genetic profile on the cognitive functions among Amyotrophic Lateral Sclerosis Tunisian patients	20
Influence of the level of education on cognitive function in Parkinson’s disease	20
Toward preventive interventions in developmental coordination disorder: in need of early behavioral markers?	20
Effectiveness, safety, and quality of life outcomes of neurotoxin injections in the treatment of essential tremors: a systematic review	20
Chronic exposure to a synthetic cannabinoid alters cerebral brain metabolism and causes long-lasting behavioral deficits in adult mice	20
Illness perceptions in pre-operative Parkinson’s disease patients	20
Regulation of circadian gene activity in fibroblasts from ADHD patients through Rosiglitazone: a pilot study	19
Comparative efficacy and safety of botulinum neurotoxin type A in blepharospasm and hemifacial spasm: a systematic review and Bayesian network meta-analysis	19
The corticospinal tract in multiple sclerosis: correlation between cortical excitability and magnetic resonance imaging measures	19
Caregiver burden of parkinsonian patients with impulse control disorders, depression and apathy	19
A call to action: revitalizing the German parkinson’s research ecosystem post-pandemic	19
Ischemic stroke and transient ischemic attack associated with neuroborreliosis: a Danish retrospective cohort	18
The relationship of early life adversity and physiological synchrony within the therapeutic triad in horse-assisted therapy	18
Axial postural abnormalities and pain in Parkinson’s disease	18
Obesity-related RNA m6A demethylase gene FTO rs1421085 is associated with neuroticism in a longitudinal birth cohort study	17
Constipation and pain in Parkinson’s disease: a clinical analysis	17
MeDeMSA care study protocol: developing personalized best medical care with integrated mobile palliative and telemedicine support for individuals with multiple system atrophy	16
Effects of acute physical activity on interference control in children with and without ADHD: a crossover ERP study from the Break4Brain project	16
Population pharmacokinetic analyses comparing immediate-release levodopa/carbidopa, controlled-release levodopa/carbidopa, and IPX203. Findings from a phase 1 study in healthy volunteers	16
Insulin resistance: fueling oxidative stress and neurodegeneration	16
The brainstem reticular formation pivots abnormal neural transmission in the course of Anorexia Nervosa	15
Update on sleep disorders in advanced Parkinson’s disease: a narrative review	15
Neuroscience and addiction research: current advances and perspectives	15
Is there a link between multiple sclerosis and Alzheimer disease? A critical note	15
Linking diet, gut microbiota, and metabolites to Parkinson’s disease risk: a shotgun metagenomic comparison of Japanese and Taiwanese cohorts	15
Potentially inappropriate medications according to PRISCUS list and FORTA (Fit fOR The Aged) classification in geriatric psychiatry: a cross-sectional study	15
Psychological, neuroendocrine and inflammatory stress responses in women after miscarriage or stillbirth: investigating early psychobiological adaptations to potential traumatic events	15
Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease	15
Advanced therapy in advanced Parkinson’s disease: money’s too tight to mention	15
Drug repurposing and new drug targets: perspectives for novel treatment options in mental health disorders	15
Retraction Note: Expression of heat shock protein (HSP 72 kDa) during acute methamphetamine intoxication depends on brain hyperthermia: neurotoxicity or neuroprotection?	15
Genetic and molecular mechanisms of the FOXP2-CNTNAP2 pathway in Autism spectrum disorders and speech disorders	14
Autism Spectrum Disorder and auditory sensory alterations: a systematic review on the integrity of cognitive and neuronal functions related to auditory processing	14
The two-network framework of number processing: a step towards a better understanding of the neural origins of developmental dyscalculia	14

Visual memory in Parkinson’s Disease: a non-graphomotor approach to assessment	14
Effects of association between resveratrol and ketamine on behavioral and biochemical analysis in mice	14
MAOA methylation is associated with impulsive and antisocial behaviour: dependence on allelic variation, family environment and diet	14
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone	14
Pharmacogenetics in advanced Parkinson’s disease	14
Serum glial fibrillary acidic protein is elevated in early-stage late-onset essential tremor and associated with tremor progression	14
Sleep disorders among frontline nurses after the COVID-19 outbreak: a large-scale cross-sectional study	14
Type A monoamine oxidase; its unique role in mood, behavior and neurodegeneration	14
In situ stoichiometry amounts of p62 and poly-ubiquitin exceed the increase of alpha-synuclein during degeneration of catecholamine cells induced by autophagy inhibition in vitro	14
Active electrode location does not influence weight gain after subthalamic nucleus deep brain stimulation surgery in Parkinson disease	14
Exploring developmental trajectories throughout adolescence of children with autism spectrum disorder without intellectual disability	13
Reduced cerebrospinal fluid taurine is associated with nigrostriatal dopaminergic deficits in drug-naïve Parkinson’s disease	13
Atrophy of cerebellar lobule VI and primary motor cortex in cervical dystonia - a region of interest-based study	13
Characteristics of behavioural addiction in Parkinson’s disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case–control study	13
Language in autism: domains, profiles and co-occurring conditions	13
Psychosis in Huntington disease: a short update	13
Exploring transferability in psychiatric interventions: a conceptual framework	13
Creutzfeldt-Jakob disease in the Philippines: diagnostic and management challenges from the first multicenter registry	12
Sexual dysfunction in men with young onset Parkinson's disease	12
Resting-state EEG changes associated with cognitive decline in Parkinson’s disease: a systematic review	12
Perceived social support declines after deep brain stimulation surgery in patients with Parkinson’s disease	12
The natural course of idiopathic cervical dystonia	12
Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?	12
The impact of cerebral vasomotor reactivity on cerebrovascular diseases and cognitive impairment	12
The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson’s disease	12
Issues for patchy tissues: defining roles for gut-associated lymphoid tissue in neurodevelopment and disease	12
Impact of device-aided therapies on quality of life in patients with Parkinson’s disease. A comparative multicenter observational study	12
Stress and resilience: cortisol hypo-response to acute stress in non-resilient individuals	12
Transdiagnostic monoamine-based subtyping for attention-deficit/hyperactivity disorder and autism spectrum disorder via unsupervised machine learning	12
Memantine: updates from the past decade and implications for future novel therapeutic applications	11
Cognitive impairment in Parkinson’s disease and other parkinsonian syndromes	11
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease	11
Clinimetrics of the Italian version of the Montreal Cognitive Assessment (MoCA) in adult-onset idiopathic focal dystonia	11
Parkinson’s disease, aerobic exercise and photobiomodulation: a randomised controlled trial	11
Correction: Deep brain stimulation for Parkinson’s disease in India: an expert consensus on availability, affordability, and eligibility by the Parkinson’s research alliance India (PRAI)	11
Maternal separation and its developmental consequences on anxiety and parvalbumin interneurons in the amygdala	11
Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide	11
Writing tremor in Parkinson’s disease: frequency and associated clinical features	11
Oligodendrocytes matter: a review of animal studies on early adversity	11
Investigation of the nonmotor symptoms in patients with STN-DBS therapy in comparison with those without STN-DBS	11
Pesticides and parkinson’s disease: causal relationship at the population and individual level?	11
Depression and apathy in frontotemporal dementia: a short assessment of facts and outlook	10
Depression in dementia with Lewy bodies: a critical update	10
Unveiling the link between chronic pain and misuse of opioids and cannabis	10
Therapeutic use of medical Cannabis in neurological diseases: a clinical update	10
High-dose glucocorticoids in COVID-19 patients with acute encephalopathy: clinical and imaging findings in a retrospective cohort study	10
Unraveling mGluR5 dysfunction in autism spectrum disorder: a multi-level analysis of genetic, molecular, and neurobiological mechanisms	10
Psychosis in multiple sclerosis—a narrative review of an underestimated, but clinically significant problem	10
Neuromarkers in addiction: definitions, development strategies, and recent advances	10
RNA sequencing of the thalamus and rostral ventral medulla in rats with chronic orofacial pain	10
If you can't be with the one you love, love the one you're with (C, S, N & Y)	10
Transcriptional dysregulation in the cerebellum triggered by oligodendroglial α-synucleinopathy: insights from a transgenic mouse into the early disease mechanisms of MSA	10
Tips and tricks in tremor treatment	10
Patterns of striatal dopamine depletion and motor deficits in de novo Parkinson’s disease	10
Posttraumatic growth and wellbeing in three countries after COVID-19: analysis using a random intercept cross-lagged panel model	10
Caring for persons with X-linked dystonia-parkinsonism in Metro Manila: insights into the burden of family caregivers	10
Botulinum toxin treatment for hemifacial spasm: harmonising neurological and aesthetic outcomes	10
Usability of the digit-tracking technique in a geriatric population of inpatients with and without neurocognitive disorders: The DIGICOG-start study	10
The prevalence of gastrointestinal dysfunction and its impact on quality of life in Parkinson’s disease	10
Developing Botulinum Toxin Drugs: Unexpected Challenges	10
Plasma prolactin and symptoms of schizophrenia	10
Myopathies in clinical care: a focus on treatable causes	10
A sporadic Parkinson’s disease model via silencing of the ubiquitin–proteasome/E3 ligase component, SKP1A	9
Depression and anxiety in multiple sclerosis. Review of a fatal combination	9
HDL cholesterol indicates neurodegenerative vulnerability in dementia with lewy bodies	9
Motor and non-motor improvements following short-term multidisciplinary day-clinic care in Parkinson´s disease	9
Environmental opportunities facilitating cognitive development in preschoolers: development of a multicriteria index	9
EEG neurosubtyping of infants predicts language trajectories	9
Expanding the phenotypic spectrum of THAP1 dystonia: a scoping review with an illustrative case of late-onset focal limb dystonia	9
How to treat cardiovascular autonomic failure in Parkinson’s disease	9
Cognitive reappraisal training as an intervention in patients with functional movement disorders: a placebo-controlled EEG pilot study	9
Post-COVID: a specific neuropsychological profile in performance deficits	9
The brain and heart-axis in neurodegeneration and cardiovascular disease	9
Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations	9
Mild cognitive impairment in amyotrophic lateral sclerosis: current view	9
Advanced is advanced is advanced is advanced	9
Catecholamines and Parkinson’s disease: tyrosine hydroxylase (TH) over tetrahydrobiopterin (BH4) and GTP cyclohydrolase I (GCH1) to cytokines, neuromelanin, and gene therapy: a historical overview	9
Mild cognitive impairment in Huntington’s disease: challenges and outlooks	8
Altered platelet function in persistent depressive disorder: a study of density subpopulations and fibrinogen binding	8
Neuropathology in genetic Parkinson’s disease: a focused review of pathological and clinical findings	8

Correlation between the MNCD classification-based staging of Parkinson’s disease and quality of life: a cross-sectional study	8
The heterogeneity of Parkinson’s disease	8
Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome	8
The efficacy of acoustic-based articulatory phenotyping for characterizing and classifying four divergent neurodegenerative diseases using sequential motion rates	8
A smartphone-based tapping task as a marker of medication response in Parkinson’s disease: a proof of concept study	8
The effect of recombinant botulinum neurotoxin A on neuropathic pain in the spared nerve injury mouse model	8
Mediating roles of attention-deficit/hyperactivity disorder symptom severity and self-control on the relationship between adverse childhood experiences and adult aggression	8
Differential diagnosis of Huntington’s disease− neurological aspects of NKX2-1-related disorders	8
The akinetic crisis in Parkinson´s disease- the upper end of a spectrum of subacute akinetic states	8
Nonmotor symptoms of craniocervical dystonia: a multicentre international study—using the Dystonia nonmotor symptoms questionnaire	8
A narrative review of clinical and non-clinical determinants of health-related quality of life in advanced Parkinson’s disease	8
Psychotherapies in opioid use disorder: toward a step-care model	8
Correction: The neural structures of theory of mind are valence-sensitive: evidence from three tDCS studies	8
The pathobiological basis of depression in Parkinson disease: challenges and outlooks	8
The relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study	8
Parkinson´s day-clinic: which patients should be selected and what services should be offered for successful therapy?	8
The sex-specific relationship of ghrelin and cognition in Chinese han first-episode drug-naive major depressive disorder	8
Genes critical for development and differentiation of dopaminergic neurons are downregulated in Parkinson’s disease	7
A structured framework for emotion-cognition dynamics: Implications for assessment and intervention	7
Parkinson’s disease-subjective cognitive decline and health-related quality of life	7
Lifestyle medicine in Parkinson’s disease	7
Methods to detect anxiety in Parkinsons’ disease	7
Iron and copper ions accelerate and modify dopamine oxidation to eumelanin: implications for neuromelanin genesis	7
Neurogenic orthostatic hypotension in Parkinson’s disease: is there a role for locus coeruleus magnetic resonance imaging?	7
Driving innovation in addiction treatment: role of transcranial magnetic stimulation	7
Genetic and environmental mouse models of autism reproduce the spectrum of the disease	7
Drug interactions in a sample of inpatients diagnosed with cannabis use disorder	7
Facial emotion recognition deficits are associated with hypomimia and related brain correlates in Parkinson’s disease	7
Manufacture of the first FDA-approved batches of 900 kilodalton crystalline type a botulinum toxin for clinical use: a personal remembrance	7
Mild cognitive impairment in multiple system atrophy: a brain network disorder	7
The multifaceted role of ASICs channels into the nervous system and their potential use as a therapeutic target for neuro-disorders	7
The impact of short-term blood pressure variability on cognitive decline in Parkinson’s disease patients without co-morbidities	7
Screening speech disorders in progressive neurological diseases via long-term average spectrum	7
Cognition and Activity of Daily Living Function in people with Parkinson’s disease	7
From parents to children: associations of traffic risks with impulsivity, family relationships and serotonin transporter genotype	7